An Open Label, Dose-Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies

Study Summary

This study is in 2 parts. The main aims of the 1st part of the study are to check if people with advanced solid tumors or cancers in the immune system (lymphomas) have side effects from TAK-981, and to check how much TAK-981 they can receive without getting side effects from it. The main aims of the 2nd part of the study are to learn if the condition of people with specific cancers improves after treatment with TAK-981. Another aim is to check for side effects from TAK-981. In the 1st part of the study, participants will receive TAK-981. In the 2nd part of the study, participants with specific tumor types will receive TAK-981 at the recommended phase 2 dose determined during the 1st part of the study. In both parts of the study, participants can receive TAK-981 for up to 1 year or longer if their condition stays improved. Participants will receive TAK-981 through vein.

Interventions

Study Locations

Facility	City	State	Country
University of California San Diego Moores Cancer Center	La Jolla	California	United States
Massachusetts General Hospital	Boston	Massachusetts	United States
Barbara Ann Karmanos Cancer Institute	Detroit	Michigan	United States
HealthPartners Cancer Care Center - Regions Hospital	Saint Paul	Minnesota	United States
University Hospitals Seidman Cancer Center	Cleveland	Ohio	United States
Fox Chase Cancer Center	Philadelphia	Pennsylvania	United States
The University of Texas MD Anderson Cancer Center	Houston	Texas	United States
Froedtert and the Medical College of Wisconsin	Milwaukee	Wisconsin	United States

Official Trial Information

View on ClinicalTrials.gov